Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
Tóm tắt
Adalimumab has been used successfully in the treatment of psoriasis. The objective of the study is to compare the efficacy, safety, and immunogenicity between HLX03, an adalimumab biosimilar, and adalimumab in Chinese patients with moderate-to-severe plaque psoriasis. In this double-blind, active-controlled, parallel-group study, 262 patients with moderate-to-severe plaque psoriasis were randomized (1:1) to receive HLX03 or adalimumab (80 mg at week 1, 40 mg at week 2, and then 40 mg every 2 weeks) for 48 weeks. The primary endpoint was improvement in Psoriasis Area and Severity Index (PASI) score at week 16 comparing to baseline. Equivalence was demonstrated if 95% confidence interval (CI) of the between group difference fell within the equivalence margins of ± 15%. Other efficacy endpoints, safety and immunogenicity were also evaluated. In the full analysis set, PASI improvements at week 16 was 83.5% (n = 131) in the HLX03 group and 82.0% (n = 130) in the adalimumab group, with a least-square-mean difference of 1.5% (95% CI − 3.9% to 6.8%). There were no significant between-group differences in all secondary efficacy analyses including proportion of patients achieving ≥ 75% improvement from baseline PASI (PASI 75), physician global assessment (PGA) 0/1 (clear or almost clear) and change in dermatology life quality index (DLQI) score. The incidences of adverse events and the proportion of patients with antidrug antibodies were also comparable between the two treatment groups. HLX03 demonstrated equivalent efficacy, similar safety and immunogenicity to reference adalimumab, supporting its development as an alternative treatment for patients with plaque psoriasis in China. Chinadrugtrials.org.cn, CTR20171123 (November 27, 2017); ClinicalTrials.gov, NCT03316781 (October 20, 2017). Plaque psoriasis is a chronic, autoimmune, inflammatory skin disease associated with significant morbidity and reduced quality of life. In China, the prevalence of plaque psoriasis increased four-fold between 1987 and 2012. Adalimumab is a biologic antibody used to treat plaque psoriasis globally. However, high treatment costs remain as a significant barrier to adalimumab therapy. Therefore, HLX03 has been developed as an adalimumab (Humira®) biosimilar, which is almost identical to the licensed reference adalimumab, but less expensive and more accessible to patients. In this randomized clinical trial, the efficacy (ability of a drug to produce the desired treatment effects), safety, and immunogenicity (ability of a drug to induce immune response which would affect its efficacy and safety) of HLX03 were compared with the reference adalimumab in Chinese patients with moderate-to-severe plaque psoriasis. Efficacy was evaluated by comparing the changes in severity and extent of disease using Psoriasis Area and Severity Index score between treatment initiation and week 16. Safety was monitored by adverse events, laboratory tests and vital signs. Immunogenicity was assessed by the incidence of antidrug antibodies. Among the 262 randomized patients, 131 received HLX03 and 130 received adalimumab. Both groups reported similar improvements in Psoriasis Area and Severity Index scores (between-group difference fell within the prespecified equivalence margins), and also in other efficacy evaluations. Additionally, the two treatment groups showed similar safety and immunogenicity profiles. In summary, HLX03 demonstrated equivalent efficacy to adalimumab, validating it as an alternative treatment for patients with plaque psoriasis in China.
Tài liệu tham khảo
Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663–7.
AbbVie Inc. Humira® prescribing information. https://www.rxabbvie.com/pdf/humira.pdf. Accessed 24 Aug 2020.
AbbVie Inc. Humira® Summary of product characteristics. 2020. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf. Accessed 19 Aug 2020.
National Medical Products Administration China. NMPA guidelines for clinical trials of adalimumab injection biosimilars. 2020. https://www.nmpa.gov.cn/directory/web/nmpa/images/1596531455261017949.pdf. Accessed 24 Aug 2020.
AbbVie Inc. Chinese-licensed adalimumab injection instructions. 2020. https://xiumeile.com/index.php/shuomingshu.html. Accessed 24 Aug 2020.
Zhao Y, Lai W. Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab. Patient Prefer Adherence. 2014;8:865–72.
Puig L, López-Ferrer A. Biosimilars for the treatment of psoriasis. Expert Opin Biol Ther. 2019;19(10):993–1000.
Kim H, Alten R, Avedano L, Dignass A, Gomollon F, Greveson K, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80(2):99–113.
National Medical Products Administration China. NMPA technical guidelines for development and evaluation of biosimilars. 2015. http://www.cde.org.cn/attachmentout.do?mothed=list&id=7b8967469153a13c. Accessed 24 Aug 2020.
European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed 1 Sept 2020.
WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs) 2009. https://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 1 Sept 2020.
US Food and Drug Administration. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations 2019. https://www.fda.gov/media/125484/download. Accessed 1 Sept 2020.
Al-Sabbagh A, Olech E, McClellan JE, Kirchhoff CF. Development of biosimilars. Semin Arthritis Rheum. 2016;45(5 Suppl):S11–8.
China National Medical Products Administration. Adalimumab biosimilars approved in China. http://app1.nmpa.gov.cn/data_nmpa/face3/base.jsp?tableId=25&tableName=TABLE25&title=%B9%FA%B2%FA%D2%A9%C6%B7&bcId=152904713761213296322795806604. Accessed 11 Sept 2020.
Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ. Safety and effectiveness of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis. Am J Clin Dermatol. 2020;21(4):483–91.
Tu L, Wei Q, Xie Y, Shi G, Liu H, Huang Q, et al. FRI0415 biosimilar Bat1406 versus adalimumab therapy on active ankylosing spondylitis: a randomized, double-blinded, multicenter, controlled phase 3 trial. Ann Rheum Dis. 2019;78(2):895.
Su J, Li M, He L, Zhao D, Wan W, Liu Y, et al. Comparison of the efficacy and safety of adalimumab (Humira) and the adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis: a multicenter, randomized, double-blind, parallel, phase III clinical trial. BioDrugs. 2020;34(3):381–93.
Xu H, Li Z, Wu J, Xing Q, Shi G, Li J, et al. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial. Lancet Rheumatol. 2019;1(1):e35–43.
National Medical Products Administration China. Information release of the drug approval document pending receipt on December 07, 2020. 2020. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20201207163143123.html. Accessed 18 Dec 2020.
Zhang E, Xie L, Qin P, Lu L, Xu Y, Gao W, et al. Quality by design-based assessment for analytical similarity of adalimumab biosimilar HLX03 to Humira®. AAPS J. 2020;22(3):69.
Sun J, Chen G, Wu M, Han Y, Gao H, Zhang T, et al. FRI0086 China-manufactured adalimumab biosimilar, HLX03, demonstrated pharmacokinetic equivalence and comparable safety to reference adalimumab. Ann Rheum Dis. 2019;78(2):706.
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76(6):1093–102.
Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev. 2014;13(7):751–5.
Gerdes S, Mrowietz U, Augustin M, von Ralph K, Enk A, Strömer K, et al. Biosimilars in dermatology—theory becomes reality. J Dtsch Dermatol Ges. 2018;16(2):150–60.
Markus R, McBride HJ, Ramchandani M, Chow V, Liu J, Mytych D, et al. A review of the totality of evidence supporting the development of the first adalimumab biosimilar ABP 501. Adv Ther. 2019;36(8):1833–50.
Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2018 simplified edition). Chin J Dermatol. 2019;52(4):223–30.
Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, et al. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31(1):89–95.
Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–66.
Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–15.
Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab MSG. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310.
Menter A, Thaci D, Wu JJ, Abramovits W, Kerdel F, Arikan D, et al. Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther (Heidelb). 2017;7(3):365–81.
Mansouri Y, Goldenberg G. Biologic safety in psoriasis: review of long-term safety data. J Clin Aesthet Dermatol. 2015;8(2):30–42.
Strand V, Gonçalves J, Hickling TP, Jones HE, Marshall L, Isaacs JD. Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs. 2020;34(1):27–37.
Hercogová J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020;182(2):316–26.
Gorovits B, Baltrukonis DJ, Bhattacharya I, Birchler MA, Finco D, Sikkema D, et al. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol. 2018;192(3):348–65.
Chiu HY, Wang TS, Chan CC, Lin SJ, Tsai TF. Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in chinese patients with psoriasis. Acta Derm Venereol. 2015;95(6):711–6.